Main Menu
Untitled Page
Home > Equity > Company info > Company Snapshot
13 August 2020

Search Quotes

  Enter at least 3 characters from BSE Code for a company or the company's name

Cipla Ltd (Pharmaceuticals - Indian - Bulk Drugs & Formln)

Last Price 762.10
Net Changes -15.90
Volume 7841606
Prev Close 778.00
762.10 -15.90 (-2.04%)
Date: Aug 12,2020 EOD




Index Details Pharmaceuticals - Indian - Bulk Drugs & Formln


Chart

Stock Price Details

Market Statistics

Open Price 776 Div Yield (%) 0.52
Buy (Size) 762.20(×10) Eps(Rs) 27.71
Sell (Size) 762.20(×362) Book Value (Stand.)(Rs) 215.84
Value 25053046700 Book Value(conso.)(Rs) 195.4961331
Buy Quantity 10 Market Cap(Rs.Cr) 61456.8
Sell Quantity 362 Face Value(Rs) 2
Today's High 776.95 Market Lot 1
Today's Low 755.5 AGM Date Aug
52-Week High 814.45 Book Closure Date Aug
52-Week Low 356.75 ISIN No. INE059A01026

Share Holding Pattern

  No Of shares % Share Holding
Total Foreign (Promoter & Group) 174907187 21.69
Indian (Promoter & Group) 120578409 14.96
Total of Promoter 295485596 36.65
Non Promoter (Institution) 321556763 39.88
Non Promoter (Non-Institution) 188482464 23.38
Total Non Promoter 510039227 63.26
Total Promoter & Non Promoter 805524823 99.91
Custodians(Against Depository Receipts) 746178 0.09
Grand Total 806271001 100.00

Company News

11-Aug-2020  Cipla Ltd - Cipla Limited - Analysts/Institutional Investor Me...
Cipla Ltd - Cipla Limited - Analysts/Institutional Investor Meet/Con. Call Updates

Cipla Limited has informed the Exchange about Analysts/Institutional Investor Meet/Con. Call Updates
10-Aug-2020  Cipla advances after strong Q1 results
Cipla advances after strong Q1 results

EBITDA in Q1 June 2020 was at Rs 1,049 crore, up by 16% from Rs 905 crore recorded in Q1 June 2019. EBITDA margin stood at 24.1% as 30 June 2020 as against 22.7% as 30 June 2019.

Cipla said that it has achieved zero net debt position led by strong collections and improved EBITDA.

India business grew by 16% YoY with strong growth across the three businesses. Overall South African business continued the strong growth momentum to deliver growth of 17% on a YoY basis in local currency; private business continues to outpace the market. The US business reported $135 million led by Albuterol ramp-up; 14% QoQ growth.

The company's R&D investments amounted to Rs 200 crore, representing 4.6% of the total revenue from operations.

Umang Vohra MD and Global CEO, Cipla, said: 'Extremely pleased to report our Q1FY21 performance which reflects the inherent strength of our business backed by agile and resilient operations, cost control initiatives and continued delivery on our strategic priorities.

During the quarter, our businesses actively re-imagined their operating models to drive strong growth across markets of India, South Africa, US and focused execution on cost optimization helped drive the quarter EBITDA to 24%.

Our global lung leadership aspirations continued to gain momentum along with limited competition launches in the US.'

Cipla is a global pharmaceutical company focused on complex generics, and deepening its portfolio in the markets of India, South Africa, North America, and key regulated and emerging markets.

10-Aug-2020  Cipla Ltd - Cipla Limited - Financial Result Updates
Cipla Ltd - Cipla Limited - Financial Result Updates

Financial Results Updates Please find attached letter dated 7th August 2020.
08-Aug-2020  Cipla consolidated net profit rises 20.85% in the June 2020 qu...
Cipla consolidated net profit rises 20.85% in the June 2020 quarter

Net profit of Cipla rose 20.85% to Rs 577.91 crore in the quarter ended June 2020 as against Rs 478.19 crore during the previous quarter ended June 2019. Sales rose 9.82% to Rs 4276.89 crore in the quarter ended June 2020 as against Rs 3894.46 crore during the previous quarter ended June 2019.

ParticularsQuarter Ended
 Jun. 2020Jun. 2019% Var.
Sales4276.893894.46 10
OPM %24.5223.23 -
PBDT1068.19930.89 15
PBT799.21662.89 21
NP577.91478.19 21
06-Aug-2020  Cipla Ltd up for third consecutive session
Cipla Ltd up for third consecutive session

Cipla Ltd is up for a third straight session today. The stock is quoting at Rs 733.5, up 1.57% on the day as on 12:54 IST on the NSE. The benchmark NIFTY is up around 1.24% on the day, quoting at 11239.1. The Sensex is at 38168.51, up 1.34%. Cipla Ltd has gained around 15.23% in last one month.

Meanwhile, Nifty Pharma index of which Cipla Ltd is a constituent, has gained around 15.42% in last one month and is currently quoting at 11263.75, up 1.22% on the day. The volume in the stock stood at 59.45 lakh shares today, compared to the daily average of 70.96 lakh shares in last one month.

The benchmark August futures contract for the stock is quoting at Rs 733.65, up 0.98% on the day. Cipla Ltd is up 41.52% in last one year as compared to a 3.53% jump in NIFTY and a 44.68% jump in the Nifty Pharma index.

The PE of the stock is 25.13 based on TTM earnings ending March 20.

05-Aug-2020  Cipla Ltd - Cipla Limited - Shareholders meeting
Cipla Ltd - Cipla Limited - Shareholders meeting

Cipla Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on August 27, 2020
04-Aug-2020  Cipla AGM scheduled
Cipla AGM scheduled

Cipla announced that the 84th Annual General Meeting (AGM) of the company will be held on 27 August 2020.
04-Aug-2020  Cipla Ltd - Cipla Limited - Book Closure
Cipla Ltd - Cipla Limited - Book Closure

Cipla Limited has informed the Exchange that Register of Members & Share Transfer Books of the Company will remain closed from 13-Aug-2020 to 27-Aug-2020 for the purpose of 84th Annual General Meeting. We are also enclosing herewith the copies of newspaper notice of book closure published in Business Standard (English) and Sakal (Marathi) today, i.e. 3rd August, 2020.
03-Aug-2020  Cipla Ltd up for five straight sessions
Cipla Ltd up for five straight sessions

Cipla Ltd rose for a fifth straight session today. The stock is quoting at Rs 721.65, up 0.21% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 1.29% on the day, quoting at 10930.15. The Sensex is at 37089.81, down 1.37%. Cipla Ltd has added around 13.72% in last one month.

Meanwhile, Nifty Pharma index of which Cipla Ltd is a constituent, has added around 13.91% in last one month and is currently quoting at 11148.9, up 1.16% on the day. The volume in the stock stood at 93.57 lakh shares today, compared to the daily average of 68.49 lakh shares in last one month.

The benchmark August futures contract for the stock is quoting at Rs 720.75, down 0.41% on the day. Cipla Ltd is up 39.07% in last one year as compared to a 0.62% gain in NIFTY and a 44.45% gain in the Nifty Pharma index.

The PE of the stock is 25.05 based on TTM earnings ending March 20.

03-Aug-2020  Cipla Ltd - Cipla Limited - Copy of Newspaper Publication
Cipla Ltd - Cipla Limited - Copy of Newspaper Publication

Cipla Limited has informed the Exchange that pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and in compliance with Ministry of Corporate Affairs Circular No. 20/2020 dated 5th May, 2020, we herewith enclose copies of newspaper advertisement titled 84th Annual General Meeting published in Business Standard (English) and Sakal (Marathi) on 1st August, 2020. This is for your information and record.
Incorporation Year 1935 
Registered Office Cipla House Peninsula Buss Par,Ganpatrao Kadam Mg Lower Parel,
,
Maharashtra-400013
Telephone 91-22-24826000 
Fax 91-22-24826120 
Chairman Y K Hamied
Managing Director Umang Vohra
Company Secretary Rajendra Chopra 
Auditor Walker Chandiok & Co LLP 
Face Value(Rs)
Market Lot
Listing BSE,Luxembourg,MSEI,NSE 
Registrar KFin Techologies Pvt Ltd
Karvy Selenium Tow-B,31&32 Financial Dist,Nanakramguda,Hyderabad-500032 
Toll Free number: 1800-425-5501 / 1800-103-5501
FINANCIAL TOOLS